ProPhase Labs (NASDAQ:PRPH) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.

ProPhase Labs Price Performance

PRPH opened at $0.49 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The company has a market capitalization of $11.65 million, a price-to-earnings ratio of -0.39 and a beta of -0.37. The firm’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $1.42. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48.

Hedge Funds Weigh In On ProPhase Labs

A number of hedge funds have recently bought and sold shares of PRPH. Renaissance Technologies LLC boosted its holdings in shares of ProPhase Labs by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after buying an additional 71,375 shares during the last quarter. HighTower Advisors LLC boosted its holdings in shares of ProPhase Labs by 32.2% in the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after buying an additional 57,736 shares during the last quarter. Sheets Smith Wealth Management purchased a new position in shares of ProPhase Labs in the 4th quarter worth about $158,000. Geode Capital Management LLC boosted its holdings in shares of ProPhase Labs by 26.6% in the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after buying an additional 42,793 shares during the last quarter. Finally, Perritt Capital Management Inc boosted its holdings in shares of ProPhase Labs by 129.1% in the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after buying an additional 107,068 shares during the last quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.